Matches in SemOpenAlex for { <https://semopenalex.org/work/W2104096093> ?p ?o ?g. }
- W2104096093 abstract "ABSTRACT β-Glucan particles (GPs) are purified Saccharomyces cerevisiae cell walls treated so that they are primarily β1,3- d -glucans and free of mannans and proteins. GPs are phagocytosed by dendritic cells (DCs) via the Dectin-1 receptor, and this interaction stimulates proinflammatory cytokine secretion by DCs. As the hollow, porous GP structure allows for high antigen loading, we hypothesized that antigen-loaded GPs could be exploited as a receptor-targeted vaccine delivery system. Ovalbumin (OVA) was electrostatically complexed inside the hollow GP shells (GP-OVA). Incubation of C57BL/6J mouse bone marrow-derived DCs with GP-OVA resulted in phagocytosis, upregulation of maturation markers, and rapid proteolysis of OVA. Compared with free OVA, GP-OVA was >100-fold more potent at stimulating the proliferation of OVA-reactive transgenic CD8 + OT-I and CD4 + OT-II T cells, as measured by in vitro [ 3 H]thymidine incorporation using DCs as antigen-presenting cells. Next, immune responses in C57BL/6J mice following subcutaneous immunizations with GP-OVA were compared with those in C57BL/6J mice following subcutaneous immunizations with OVA absorbed onto the adjuvant alum (Alum/OVA). Vaccination with GP-OVA stimulated substantially higher antigen-specific CD4 + T-cell lymphoproliferative and enzyme-linked immunospot (ELISPOT) responses than that with Alum/OVA. Moreover, the T-cell responses induced by GP-OVA were Th1 biased (determined by gamma interferon [IFN-γ] ELISPOT assay) and Th17 biased (determined by interleukin-17a [IL-17a] ELISPOT assay). Finally, both the GP-OVA and Alum/OVA formulations induced strong secretions of IgG1 subclass anti-OVA antibodies, although only GP-OVA induced secretion of Th1-associated IgG2c antibodies. Thus, the GP-based vaccine platform combines adjuvanticity and antigen delivery to induce strong humoral and Th1- and Th17-biased CD4 + T-cell responses. IMPORTANCE Most licensed vaccines work by promoting protective antibody responses. However, for many infectious diseases, antibody-mediated protection appears to play a relatively minor role, and vaccination has met with limited success. While live-attenuated organisms generally elicit T-cell responses, their use in vaccines is limited by the potential for causing disease. Thus, there is an urgent need for new vaccine platforms that deliver antigens in such a manner as to promote strong T-cell-mediated responses. Here we designed a novel vaccine platform consisting of yeast-derived β-glucan particles (GPs) that combines antigen delivery and adjuvant activity. GPs loaded with the model antigen ovalbumin (OVA) stimulated robust humoral and T-cell responses in mice. In addition, the cellular response was Th1 and Th17 biased. This work has implications for the design of vaccines that stimulate biased T-cell responses as well as for understanding how immunity to fungal pathogens develops." @default.
- W2104096093 created "2016-06-24" @default.
- W2104096093 creator A5035268981 @default.
- W2104096093 creator A5054141043 @default.
- W2104096093 creator A5056742280 @default.
- W2104096093 creator A5057980496 @default.
- W2104096093 creator A5081023775 @default.
- W2104096093 date "2010-08-31" @default.
- W2104096093 modified "2023-10-03" @default.
- W2104096093 title "Robust Stimulation of Humoral and Cellular Immune Responses following Vaccination with Antigen-Loaded β-Glucan Particles" @default.
- W2104096093 cites W1964465182 @default.
- W2104096093 cites W1969276201 @default.
- W2104096093 cites W1979771705 @default.
- W2104096093 cites W1982787945 @default.
- W2104096093 cites W1982895831 @default.
- W2104096093 cites W1982994377 @default.
- W2104096093 cites W1988940275 @default.
- W2104096093 cites W1990702740 @default.
- W2104096093 cites W1997276741 @default.
- W2104096093 cites W1997962485 @default.
- W2104096093 cites W1999732094 @default.
- W2104096093 cites W2006475796 @default.
- W2104096093 cites W2009382868 @default.
- W2104096093 cites W2018367888 @default.
- W2104096093 cites W2027040539 @default.
- W2104096093 cites W2052665644 @default.
- W2104096093 cites W2062254683 @default.
- W2104096093 cites W2068474015 @default.
- W2104096093 cites W2070867977 @default.
- W2104096093 cites W2079752861 @default.
- W2104096093 cites W2081287274 @default.
- W2104096093 cites W2092235636 @default.
- W2104096093 cites W2092826070 @default.
- W2104096093 cites W2100087187 @default.
- W2104096093 cites W2108093856 @default.
- W2104096093 cites W2109724505 @default.
- W2104096093 cites W2112133235 @default.
- W2104096093 cites W2118201373 @default.
- W2104096093 cites W2119941820 @default.
- W2104096093 cites W2123093300 @default.
- W2104096093 cites W2125898296 @default.
- W2104096093 cites W2129374849 @default.
- W2104096093 cites W2134250807 @default.
- W2104096093 cites W2135442912 @default.
- W2104096093 cites W2137670912 @default.
- W2104096093 cites W2139455129 @default.
- W2104096093 cites W2143834135 @default.
- W2104096093 cites W2147497666 @default.
- W2104096093 cites W2149260562 @default.
- W2104096093 cites W2158311244 @default.
- W2104096093 cites W2170533080 @default.
- W2104096093 cites W2172299164 @default.
- W2104096093 cites W2417414326 @default.
- W2104096093 doi "https://doi.org/10.1128/mbio.00164-10" @default.
- W2104096093 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2925077" @default.
- W2104096093 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20802824" @default.
- W2104096093 hasPublicationYear "2010" @default.
- W2104096093 type Work @default.
- W2104096093 sameAs 2104096093 @default.
- W2104096093 citedByCount "128" @default.
- W2104096093 countsByYear W21040960932012 @default.
- W2104096093 countsByYear W21040960932013 @default.
- W2104096093 countsByYear W21040960932014 @default.
- W2104096093 countsByYear W21040960932015 @default.
- W2104096093 countsByYear W21040960932016 @default.
- W2104096093 countsByYear W21040960932017 @default.
- W2104096093 countsByYear W21040960932018 @default.
- W2104096093 countsByYear W21040960932019 @default.
- W2104096093 countsByYear W21040960932020 @default.
- W2104096093 countsByYear W21040960932021 @default.
- W2104096093 countsByYear W21040960932022 @default.
- W2104096093 countsByYear W21040960932023 @default.
- W2104096093 crossrefType "journal-article" @default.
- W2104096093 hasAuthorship W2104096093A5035268981 @default.
- W2104096093 hasAuthorship W2104096093A5054141043 @default.
- W2104096093 hasAuthorship W2104096093A5056742280 @default.
- W2104096093 hasAuthorship W2104096093A5057980496 @default.
- W2104096093 hasAuthorship W2104096093A5081023775 @default.
- W2104096093 hasBestOaLocation W21040960931 @default.
- W2104096093 hasConcept C147483822 @default.
- W2104096093 hasConcept C185592680 @default.
- W2104096093 hasConcept C203014093 @default.
- W2104096093 hasConcept C2776090121 @default.
- W2104096093 hasConcept C2776946954 @default.
- W2104096093 hasConcept C2777863537 @default.
- W2104096093 hasConcept C2779053233 @default.
- W2104096093 hasConcept C86803240 @default.
- W2104096093 hasConcept C8891405 @default.
- W2104096093 hasConceptScore W2104096093C147483822 @default.
- W2104096093 hasConceptScore W2104096093C185592680 @default.
- W2104096093 hasConceptScore W2104096093C203014093 @default.
- W2104096093 hasConceptScore W2104096093C2776090121 @default.
- W2104096093 hasConceptScore W2104096093C2776946954 @default.
- W2104096093 hasConceptScore W2104096093C2777863537 @default.
- W2104096093 hasConceptScore W2104096093C2779053233 @default.
- W2104096093 hasConceptScore W2104096093C86803240 @default.
- W2104096093 hasConceptScore W2104096093C8891405 @default.
- W2104096093 hasIssue "3" @default.
- W2104096093 hasLocation W21040960931 @default.
- W2104096093 hasLocation W21040960932 @default.